is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Singapore, February 2019. Rare cell detection specialist X-ZELL has officially confirmed the launch of the world’s first 9-colour immunostaining system.
Originally designed to enable the company’s headline-making research into next-generation biomarkers, the long-anticipated production version of the X-ZELL Cryoimmunostaining™ Suite is set to debut at the 2019 Medlab Asia Pacific trade show, to be held at Singapore’s Suntec Convention Centre from 26-28 March.
Comprised of two high-performance devices, the CryoFixator™ and the CryoStainer™, the system allows researchers to apply up to nine biomarkers* at a time to cells fixated on standard laboratory slides – making it one of the most powerful cytology tools in the world.
“We have had tremendous success using our Cryoimmunostaining™ technology as part of our own research over the past two years,” said X-ZELL CEO, Dr Sebastian Bhakdi – explaining the system serves as the gateway to next generation, 9-colour fluorescence microscopy, a breakthrough technique he invented in 2018 in collaboration with Mahidol University in Bangkok.
“Nine-colour immunostaining has not only enabled us to detect a new type of circulating cell that had previously been considered undetectable in clinical routine, but also allowed us to develop liquid biopsies that can reliable detect clinically significant prostate cancer at the earliest stages.
“We believe now is the time to make next-generation single-cell immunofluorescence cytology accessible to researchers worldwide.”
Designed & manufactured in Singapore, the X-ZELL Cryoimmunostaining™ Suite will initially be available for research use only.
To book an appointment with an X-ZELL representative during Medlab Asia Pacific 2019, please contact [email protected]
For media enquiries, please contact [email protected]
*X-ZELL’s Cryoimmunostaining™ Suite has been validated for 16 different, primary fluorophore-labelled antibodies, up to nine of which can be utilised in parallel to enable the fast and direct visualization and characterization of membrane, cytosolic and nuclear antigen expression in single cells as well as organ tissue – all with minimal crosstalk between fluorescence channels and no downstream application of advanced mathematical algorithms.
Head of Marketing & Communications
+61 425 699 879 (AUS & Global)
+66 6 2197 8788 (THA)
10 June 2020: 9:30 – 17:00
11 June 2020: 9:30 – 17:00
12 June 2020: 9:30 – 16:00